EspanaSalude.Org

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

October 22, 2015

Presented Clinical Findings at the AHA's Joint Annual Meeting. In March, the Company announced presentation of findings from a retrospective clinical study on weight management conducted in collaboration with Stanford University that determined whether individuals who were assigned diets that were appropriate for their genotype could lose more weight than those who followed a diet inappropriate for their genotype, as determined by the Interleukin Genetics proprietary Weight Management Genetic Test. The findings showed statistically significant greater weight loss, metabolic benefit and other improvements when compared to individuals on diets not matched to their genotype.

Received Approval to Sell Heart Health Genetic Test in Certain European Countries. In January, the Company announced that LABEC Pharma met European regulatory guidelines to sell Interleukin Genetics' Heart Health genetic test. The test, which helps to identify individuals at elevated risk for early heart attack, will be marketed to physicians in Spain and Portugal by LABEC Pharma under the product name CardioHealth??.

Raised $5.3 Million in Registered Direct Offering. In March, the Company announced that it received commitments from certain institutional investors to purchase approximately $5.3 million of securities in a registered direct offering. The investors purchased an aggregate of 4,375,002 units for $1.20 per unit, with each unit consisting of a share of common stock and a warrant to purchase 0.40 of a share of common stock. The warrants are exercisable at $1.30 per share and expire in five years. Net proceeds to the Company after fees and expenses were approximately $4.9 million.

SOURCE Interleukin Genetics, Inc.